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Commentary
In early 2007, following a report of elevated 
lead levels in certain commercial vitamin prod-
ucts, the U.S. Food and Drug Administration 
(FDA) conducted a nationwide survey in the 
United States to determine the Pb content 
in 324 multivitamin/mineral products (here-
after, vitamin products) labeled for use by 
women and children (U.S. FDA 2008). Four 
categories of vitamin products were examined, 
defined by the population groups for whom 
they are intended: young children (0‒6 years 
of age), older children (≥ 7 years of age), preg-
nant or lactating women, and adult women.
To estimate the range of Pb exposures that 
might result from consumption of each vita-
min product in the study, the FDA multiplied 
the amount of Pb in each product (the mass 
fraction) by the maximum recommended 
daily consumption, as indicated on the pack-
age label instructions (Mindak et al. 2008).
The amounts of Pb measured in these 324 
vitamin products ranged from nondetectable 
to 2.88 µg/day in products intended for young 
children; from 0.0276 to 1.78 µg/day in vita-
mins for older children; from nondetectable to 
8.97 µg/day in vitamins for pregnant and lac-
tating women; and from 0.0146 to 4.92 µg/
day in vitamins for other adult women.
To determine whether estimated Pb con-
sumption from these vitamin products posed 
a hazard to human health, the FDA compared 
estimated Pb exposures with safe/tolerable 
exposure levels previously developed for age 
and sex groups, termed provisional total tol-
erable intake (PTTI) levels (Carrington and 
Bolger 1992). These PTTI levels were devel-
oped by the FDA in 1992 and are based on the 
assumption that food is the sole source of Pb 
exposure. Their goal was to predict the dietary 
intakes that would result in a blood lead level 
(BLL) of 10 µg/dL for children and pregnant 
or lactating women and of 30 µg/dL for other 
adults, including women of childbearing age. 
Accordingly, PTTI levels for dietary intake of 
Pb were set at 6 µg/day for young children and 
25 µg/day for pregnant or lactating women.
Through this comparison, the FDA deter-
mined that five vitamin products would have 
resulted in exposures that exceeded 4 µg/day, 
the highest being 8.97 µg/day in a product 
labeled for pregnant or lactating women. The 
highest exposure estimate for children’s vita-
mins was 2.88 µg/day. Median Pb exposure 
was 0.576 µg/day. The FDA concluded that Pb 
concentrations in all vitamin products exam-
ined are below PTTI levels for all groups and 
that, therefore, none of the products pose a 
hazard to health. 
Misguided Assumptions
The FDA’s conclusion that Pb concentrations 
in commercial vitamin products pose no haz-
ard to human health is based on outdated 
assumptions. It fails to consider recent litera-
ture on the potentially deleterious effects that 
low-level chronic Pb exposure may have on 
vulnerable populations. 
Improper use of the Centers for Disease 
Control and Prevention’s blood Pb action 
level of 10 µg/dL. In 1991, the U.S. Centers 
for Disease Control and Prevention (CDC) 
determined that primary prevention activities 
in children should begin at BLLs > 10 µg/dL 
(CDC 1991). It has become increasingly clear 
that the inverse relationship between blood 
Pb concentrations and health and develop-
mental effects extends well below 10 µg/dL. 
Numerous epidemiologic studies over the 
past three decades have shown no evidence 
of a threshold for such effects, and, indeed, 
the indications are that the slope of the dose–
response curve steepens as it approaches zero 
(Lanphear et al. 2005). Studies have repeatedly 
linked BLLs < 10 µg/dL in children 1–5 years 
of age with decreased IQ and impaired cogni-
tion (e.g., Bellinger and Needleman 2003), and 
associations with attention and behavior prob-
lems are becoming increasingly evident as well 
(Braun et al. 2006; Needleman et al. 1996). 
Strong and long-lasting neurobehavioral effects 
occur with BLLs as low as 2 µg/dL (Canfield 
et al. 2003; Jusko et al. 2008). A recent risk 
assessment by the California Environmental 
Protection Agency calculated that a 1-µg/dL 
change in BLL in the range of 1–10 µg/dL 
results in a population-level decrement of one 
IQ point (California Environmental Protection 
Agency 2009). Even a 1-point change in Full 
Scale IQ score, although within the standard 
error of an individual’s single measurement, 
is still highly significant on a population basis 
(Bellinger 2004). 
Failure to consider the heightened vul-
nerability of the developing fetus. The FDA 
  analysis assumes that a blood level of 10 µg/dL 
is a threshold below which no adverse effects 
occur to the fetus and that a BLL of 30 µg/dL 
is a threshold level for adults, including non-
pregnant women of childbearing age. 
Maternal BLLs of approximately 10 µg/dL 
have been linked to increased risks of preg-
nancy hypertension, spontaneous abortion, 
and reduced neurobehavioral development in 
offspring. Somewhat higher maternal Pb lev-
els have been linked to reduced fetal growth 
(Gardella 2001). Pb crosses the placenta from 
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the maternal to the fetal circulation without 
impediment, and BLLs in mother and fetus 
are virtually identical. Developing fetuses and 
young children absorb Pb more readily than 
adults, and Pb enters the brain quite freely. 
Some of the neurobehavioral effects related 
to Pb exposure during fetal neurodevelop-
ment appear to be permanent and persist into 
childhood (Bellinger et al. 1987; Gomaa et al. 
2002; Shen et al. 1998). The FDA’s PTTI lev-
els for Pb are at least one order of magnitude 
higher than the maximum allowable dose level 
of 0.5 µg/day, established by the California 
Environmental Protection Agency under the 
Safe Drinking Water and Toxic Enforcement 
Act for chemicals with known reproductive 
toxicity (California Environmental Protection 
Agency 2007).
Using dietary Pb intake as the basis 
for daily Pb exposure. A second shortcom-
ing in the FDA’s analysis is the assumption, 
embodied in the PTTI levels, that diet is the 
only source of exposure to Pb. In fact, there 
has been a marked reduction over the past 
20 years of Pb exposure from food sources 
due to the elimination of solder in food and 
soft drink cans in the 1980s. Thus, today lead 
paint and dust account for up to 70% of ele-
vated BLLs in U.S. children. The contribution 
of dust and soil is most critical for children 
1‒3 years of age, typically the age with the 
highest BLLs and greatest hand-to-mouth 
behaviors (Levin et al. 2008). The FDA analy-
sis omits any consideration of these nonfood 
sources of exposure to Pb. 
Further shortcomings. A third short  coming 
in the FDA analysis is its assumption that 
nonpregnant women of childbearing age may 
be considered equivalent to other adults in 
terms of their PTTI levels. This assumes that a 
woman ingests only a single source of Pb and 
that this exposure is terminated at the onset 
of pregnancy. The use of the adult PTTI level 
for pregestational women reflects the release of 
endogenous bone Pb that accumulated before 
pregnancy, but ignores the possible additive 
effects of fetal exposure to exogenous Pb from 
continued ingestion during pregnancy.
A fourth and final shortcoming in the 
FDA estimates is the assumption that all per-
sons consume vitamins in doses that adhere 
to label instructions. In fact, previous studies 
of food consumption indicate a wide range of 
exposures in which some persons significantly 
exceed recommended consumption levels 
(National Research Council 1993). Higher 
exposures that result either from accidental 
overingestion or off-label use would lead to an 
increase in the overall Pb exposure risk.
Conclusion
Reconsideration of the FDA’s conclusions 
and recommendations would appear war-
ranted. The FDA should use the most current 
information available to guide future recom-
mendations, especially when considering the 
health of children and pregnant women. Pb 
is a known neurotoxicant, and its presence 
in a readily available and widely consumed 
product such as vitamin supplements pro-
vides an unnecessary and preventable source 
of exposure.
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